Clinical Trial Update: Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant [Phase 1]

View source ↗

Summary

Phase 1 trial update assessing the safety and immune response of an HIV vaccine (SF-2 gp120) with or without MTP-PE/MF59 adjuvant.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• MF59 adjuvant (MF59)
• MTP-PE adjuvant (MTP-PE)
• SF-2 gp120 HIV vaccine (gp120-based HIV vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED